Skip to Main Content

Paper Details

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.
J Immunother Cancer
15
2022
Author NameAffiliation
Barak RotblatBen-Gurion University of the Negev
Luc G T MorrisMemorial Sloan Kettering Cancer Center
  • 1 - 2

Datasets

Release 1.2